Oppenheimer Holdings, Inc. restated a "hold" rating on shares of Endo International PLC in a report on Sunday, July 23rd. Deutsche Bank AG set a $13.00 price target on Endo International PLC and gave the stock a buy rating in a report on Wednesday, August 9th.
WARNING: "Endo International PLC (ENDP) Price Target Cut to $7.00" was first published by BBNS and is the sole property of of BBNS. Finally, ValuEngine raised Endo International PLC from a hold rating to a buy rating in a research report on Monday, October 2nd. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of "Hold" and an average price target of $11.67.
Endo International plc (NASDAQ:ENDP) closed its last session at $6.69. These ratios are important while doing valuation of the company or the shares of the company. The company rocked its 52-Week High of $18.63 and touched its 52-Week Low of $5.85. For the current year the company's revenue estimates are $3.46 Billion compared to low analyst estimates of $3.4 Billion and high estimates of $3.5 Billion according to the prediction of 21 analysts. Its Average True Range (ATR) value figured out at 1.23. Endo Int'l Plc (NASDAQ:ENDP)'s price sits -15.42% off from its 50-day moving average of $8.02 and -35.84% away from the stock's 200-day moving average which is $10.31. The company reported $0.91 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.85 by $0.06.
The revenue of U.S. Generics Base business dropped 27% over third-quarter 2016; this drop mainly resulted from the impact on Q3 2017 related to 2017 and 2016 competitive events, previously reported product discontinuances and the sustained impact on pricing following consolidation among Endo's trade accounts.
Investors and Traders continue to monitor technical levels of shares of Endo International plc (ENDP).
Royal Bank Of Canada lowered the price target on November 10 changing the forecast from $9.00 to $8.00 and issued a "Sector Perform" rating. If you are accessing this story on another site, it was stolen and republished in violation of US and global trademark & copyright law.
On October 17, 2017 Royal Bank Of Canada released guidance on ENDP and giving a rating of "Hold" and a price target of $9.00. The shares were purchased at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
The company now has an insider ownership of 0.5 Percent and Institutional ownership of 89.5 Percent.
A number of hedge funds have recently bought and sold shares of ENDP. Alps Advisors Inc. raised its holdings in shares of Endo International PLC by 9.3% in the third quarter. Capstone Asset Management Co. boosted its stake in shares of Endo International PLC by 3.1% in the second quarter. The company's past year sales total was 1.24 Million. Its stake was valued at $95,123,000 a decrease of 10.1% as of quarter end. Mizuho reiterated a "buy" rating and issued a $14.00 target price (down from $19.00) on shares of Endo International PLC in a report on Tuesday, September 12th. Meeder Asset Management Inc. now owns 48,699 shares of the company's stock valued at $544,000 after buying an additional 677 shares in the last quarter. Finally, Riverhead Capital Management LLC increased its position in Endo International PLC by 64.4% during the 2nd quarter. The share last price represents downtick move of -62.80% in value from company's 52-Week high price and shows 20.10% above change in value from its 52-Week low price.
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services.